摘要
目的:探讨肺癌患者血清中TPS、CEA和血浆中TU M2-PK的临床应用价值。方法:采用ELISA法分别检测60例肺癌患者,54例良性肺部疾病和40例健康成人血清中TPS、CEA和血浆中TU M2-PK水平,并对28例肺癌患者进行术后1个月和3个月的随访检测。结果:肺癌组TU M2-PK、TPS、CEA水平明显高于良性肺疾病组和健康对照组(P<0.05)。3种肿瘤标志物单项检测时,TPS的敏感性(78.3%)最高,TU M2-PK的准确性(83.3%)最高;多项联合检测时,以TU M2-PK+TPS+CEA组合获得的敏感性(98.3%)和准确性(89.0%)最高,但特异性(83.0%)有所降低。3种肿瘤标志物水平随临床分期(TNM)增加而升高,Ⅰ、Ⅱ期和Ⅲ、Ⅳ期比较,TPS、CEA、TU M2-PK差异有统计学意义(P<0.05)。手术治疗后,3种肿瘤标志物均较术前明显下降。结论:3种肿瘤标志物在肺癌的诊断治疗中,具有一定的临床应用价值。TU M2-PK+TPS+CEA组合可明显提高肺癌诊断的敏感性和准确性。
Objective：To investigate the clinical value of serum TPS,CEA and plasma TU M2-PK in lung cancer patients.Methods：The concentration of TPS,CEA and TU M2-PK were detected by ELISA in 60 lung cancer patients,54 benign lung disease patients and 40 healthy people.Moreover follow-up visit was undertaken at one month and three months after surgery for lung cancer patients.Results：The level of TPS,CEA and TU M2-PK were significantly higher in lung cancer than those in benign lung disease and health controls（P〈0.05）.TPS showed the highest sensitivity（78.3%） and TU M2-PK showed the highest accuracy（83.8%） in single tumor marker detection,and TU M2-PK＋TPS＋CEA showed the highest sensitivity（98.3%） and accuracy（89.0%）,but lower specificity（83.0%） in combined tumor marker detection for diagnosis of lung cancer.The level of TPS,CEA,TU M2-PK in stage Ⅲ and stage Ⅳ were evidently higher than those in stage I,Ⅱ.After operation,a marked decreasing in these values was observed.Conclusion：There was specifically clinical application value of these three tumor markers for diagnosis and cure of lung cancer.The sensitivity and accuracy can be increased with combination of TU M2-PK＋TPS＋CEA in diagnosis of lung cancer.
出处
《中国医药导报》
CAS
2011年第10期20-22,共3页
China Medical Herald
